Skip to the answer

Medroxyprogesterone

Medroxyprogesterone is a progestin hormone used in injections to prevent pregnancy (and, for one product, to manage endometriosis-associated pain) and in tablets to treat missed periods, abnormal uterine bleeding and protect the uterine lining in women taking estrogen after menopause.

Brand names ProveraAmenCurretabCycrinProdroxy +2 more
Drug class Progestin
Rx Forms 2
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 24 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

Other forms & routes:
Injection
Medroxyprogesterone at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Medroxyprogesterone is a progestin (a form of progesterone), around since about 1959 and available as a generic, best known as the Depo-Provera birth control shot (it blocks ovulation and thickens cervical mucus; one version also eases endometriosis pain), with tablets for missed periods, abnormal uterine bleeding and protecting the uterine lining during estrogen therapy. It is usually well tolerated, though the shot often brings irregular spotting at first and some weight gain. The shot can thin bones, especially in teens, so use past 2 years is discouraged unless other options fall short, and with estrogen, the tablets carry a boxed warning for blood clots, stroke, heart attack, breast cancer and probable dementia.

Clinical pearls

  • Fertility can be slow to return after the last shot, so plan to stop well before you hope to conceive.
  • Carbamazepine, phenytoin, rifampin, St. John’s wort and other enzyme-inducing drugs can make it less effective as birth control.
  • Smoking, heavy drinking, anorexia, or long-term steroids or seizure medicines add to the shot’s bone loss, so mention them first.
  • It can alter some lab results, so tell any lab or pathologist reviewing a sample that you use it.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

The boxed warning is about estrogen plus progestin therapy, including medroxyprogesterone combined with estrogen after menopause. Do not use estrogen with a progestin to prevent heart disease, heart attack, stroke or dementia.

In large studies of postmenopausal women, this combination raised the risk of blood clots in the legs and lungs, stroke, heart attack and invasive breast cancer. Women aged 65 or older had a higher risk of probable dementia (decline in brain function). It is unknown whether this applies to younger postmenopausal women.

These therapies should be used at the lowest effective dose for the shortest time that meets treatment goals. Talk regularly with your healthcare provider about whether you still need treatment.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asTablet, Injection
Earliest FDA record1959
Companies listing it with the FDA23
FDA label last updatedOct 9, 2022
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Medroxyprogesterone, written from its FDA label.

What Medroxyprogesterone is used for

▾

Medroxyprogesterone is used differently depending on the product.

  • Depo-Provera CI and medroxyprogesterone acetate injectable suspension (intramuscular): prevent pregnancy.
  • Depo-SubQ Provera 104 (subcutaneous): prevents pregnancy and manages endometriosis-associated pain.
  • Provera and medroxyprogesterone acetate tablets (oral): treat secondary amenorrhea (missed periods).
  • Provera and medroxyprogesterone acetate tablets: treat abnormal uterine bleeding due to hormonal imbalance, without an underlying cause like fibroids or uterine cancer.
  • Provera and medroxyprogesterone acetate tablets: help prevent endometrial hyperplasia in postmenopausal women with a uterus who take daily oral conjugated estrogens.

How Medroxyprogesterone works

▾

Depo-SubQ Provera 104 reduces gonadotropins, the hormones that signal the ovaries. This mainly prevents eggs from maturing and being released (ovulation). It also thickens cervical mucus, which adds to the birth control effect.

Lower estradiol levels are likely responsible for easing endometriosis-associated pain.

Medroxyprogesterone dosage

▾

How it is taken depends on the product. Always follow your prescriber and the label.

  • Depo-Provera CI and medroxyprogesterone acetate injectable suspension: a deep muscle injection about every 3 months (13 weeks). The vial or syringe is shaken well first and sites are rotated.
  • Depo-SubQ Provera 104: an injection under the skin about every 12 to 14 weeks, given only by a healthcare professional.
  • Provera and medroxyprogesterone tablets: taken by mouth daily for a set number of days, timed to the condition being treated.

Dosing details from the FDA-approved label

From the Medroxyprogesterone prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Contraception (Depo-SubQ Provera 104, subcutaneous)
    • 104 mg given subcutaneously into the anterior thigh or abdomen every 12 to 14 weeks
    • Dosage does not need to be adjusted for body weight; use for longer than 2 years is not recommended unless other methods are considered inadequate
  • Secondary amenorrhea (oral tablets)
    • 5 or 10 mg daily for 5 to 10 days
    • To induce optimum secretory transformation of an adequately estrogen-primed endometrium, 10 mg daily for 10 days
    • Therapy may be started at any time
  • Abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology (oral tablets)
    • Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg daily for 5 to 10 days
    • 10 mg daily for 10 days beginning on the 16th day of the cycle is suggested for optimum secretory transformation
  • Reduction of endometrial hyperplasia in postmenopausal women receiving daily 0.625 mg conjugated estrogens (oral tablets)
    • 5 or 10 mg daily for 12 to 14 consecutive days per month, beginning on the 1st day or the 16th day of the cycle
    • Start at the lowest dose; the lowest effective dose has not been determined
  • Prevention of pregnancy (medroxyprogesterone acetate injectable suspension, intramuscular)
    • 150 mg every 3 months (13 weeks) by deep intramuscular injection in the gluteal or deltoid muscle
Read the label’s full dosing text

DOSAGE AND ADMINISTRATION Secondary Amenorrhea Medroxyprogesterone acetate tablets may be given in dosages of 5 or 10 mg daily for 5 to 10 days. A dose for inducing an optimum secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen is 10 mg of medroxyprogesterone acetate daily for 10 days. In cases of secondary amenorrhea, therapy may be started at any time. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing medroxyprogesterone acetate therapy. Abnormal Uterine Bleeding Due to Hormonal Imbalance in the Absence of Organic Pathology Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg of medroxyprogesterone acetate may be given daily for 5 to 10 days. To produce an optimum secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen, 10 mg of medroxyprogesterone acetate daily for 10 days beginning on the 16th day of the cycle is suggested. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing therapy with medroxyprogesterone acetate. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with medroxyprogesterone acetate. Reduction of Endometrial Hyperplasia in Postmenopausal Women Receiving Daily 0.625 mg Conjugated Estrogens When estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be re-evaluated periodically as clinically appropriate (for example, 3 to 6 month intervals) to determine if treatment is still necessary (see Error! Hyperlink reference not valid. ). For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Medroxyprogesterone side effects

▾

The most common side effects reported with the injections include:

Common side effects

  • Irregular, heavy, light or spotting bleeding
  • Missed periods (amenorrhea)
  • Headache
  • Weight gain
  • Injection site reactions (pain, lumps, dimpling)
  • Vaginal infections such as yeast
  • Abdominal pain
  • Depression or mood changes
  • Vaginal infections, belly pain, acne, nausea and mood changes

When to get medical help

  • Call your doctor right away for signs of a blood clot or stroke, such as leg swelling or pain, chest pain, shortness of breath or sudden weakness.
  • Get help right away for sudden loss of vision, bulging eyes, double vision or sudden migraine.
  • Seek emergency care for signs of a severe allergic reaction (anaphylaxis).
  • Call your doctor for yellowing of the skin or eyes (jaundice) or other signs of liver problems.
  • Tell your doctor about severe belly pain, especially if you become pregnant, since it could be an ectopic pregnancy (pregnancy outside the uterus).
  • Tell your doctor if depression returns or gets worse.
  • Report bleeding that is heavy or does not stop.
  • Report lumps in the breast or any breast changes.

Medroxyprogesterone warnings and precautions

▾
  • Bone loss: the injections can significantly reduce bone mineral density, and recovery may be incomplete. Use beyond 2 years is not recommended unless other options are inadequate.
  • Blood clots: stop treatment if a clot develops, unless there are no other acceptable birth control options.
  • Breast cancer: women with a strong family history need careful monitoring, and those with a history of breast cancer should not use hormonal birth control.
  • Other: liver problems, depression, fluid retention, weight gain, lowered glucose tolerance and bleeding changes.
  • Fertility: return of ovulation can be delayed after stopping the injections.
  • STDs: the injections do not protect against HIV or other sexually transmitted diseases.

Medroxyprogesterone interactions

▾

Some drugs and herbs can reduce how well hormonal birth control works.

  • Enzyme inducers such as carbamazepine, phenytoin, rifampin, St. John’s wort, topiramate, barbiturates, bosentan, felbamate, griseofulvin and oxcarbazepine can lower hormone levels, so a back-up method may be needed.
  • HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors can change progestin levels.
  • Antibiotics: pregnancies have been reported, but studies show no consistent effect on hormone levels.
  • Lab tests, including coagulation, lipids and glucose tolerance, may be affected.

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿139 supplements and herbs with documented Medroxyprogesterone interactions, ranked by severity Check Medroxyprogesterone against a supplement or herb →

Before taking Medroxyprogesterone

▾
  • Do not use the injections if you are or might be pregnant.
  • Do not use them with a history of blood clots or cerebral vascular disease, breast cancer, significant liver disease or undiagnosed vaginal bleeding.
  • Tell your prescriber about allergies, depression, diabetes, epilepsy, migraine, asthma, and heart or kidney problems.
  • Tell your prescriber about osteoporosis risk factors, such as smoking, heavy alcohol use or long-term steroid use.
  • Breastfeeding: small amounts pass into milk, with no adverse effects noted in infants. For exclusively breastfeeding mothers, the injection is started at or after 6 weeks postpartum.
  • The injections are not indicated before a first period or after menopause.

Medroxyprogesterone overdose

▾

With estrogen plus progestin therapy, too much may cause nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness or fatigue, and withdrawal bleeding. Treatment is stopping the medicines and providing supportive care for symptoms.

What Medroxyprogesterone does in the body

▾

Progestins like Depo-SubQ Provera 104 lower gonadotropin levels, sex hormone binding globulin, and levels of steroids such as estradiol, progesterone and testosterone. Effects on cholesterol are inconsistent. Some lab values, such as clotting factors and liver tests, may rise.

How your body processes Medroxyprogesterone

▾

After a Depo-SubQ Provera 104 injection under the skin, drug levels rise within 24 hours and peak about a week later. About 86% of it binds to albumin in the blood. The liver breaks it down extensively, and most metabolites leave in the urine. Its half-life is about 40 days, which supports dosing every 12 to 14 weeks.

How to store Medroxyprogesterone

▾

Store at controlled room temperature 20° to 25°C (68° to 77°F) . Keep out of reach of children"

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

139

Supplements & herbs that interact with Medroxyprogesterone

139 supplements and herbal products have documented interactions with Medroxyprogesterone in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 3
  • Moderate · 95
  • Minor · 41
ACTIVATED CHARCOAL Major GRAPEFRUIT Major ST. JOHN'S WORT Major ACACIA RIGIDULA Moderate ADRAFINIL Moderate AFRICAN WILD POTATO Moderate AMERICAN ELDER Moderate ASTAXANTHIN Moderate +131 more
Every supplement checked against Medroxyprogesterone — ranked by severity The full interaction hub: 3 major · 95 moderate · 41 minor · every one linked to its full report. Check Medroxyprogesterone against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Medroxyprogesterone: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Medroxyprogesterone — the kind of thing our pharmacy team would talk through with you at the counter.

What is medroxyprogesterone used for?

▾
It depends on the form. The injections prevent pregnancy, and Depo-SubQ Provera 104 also manages endometriosis-associated pain. The tablets treat missed periods and abnormal uterine bleeding from hormonal imbalance, and help protect the uterine lining in postmenopausal women taking estrogen.

How often do I get the shot?

▾
Depo-Provera CI and other medroxyprogesterone injectable suspensions are given into a muscle about every 3 months (13 weeks). Depo-SubQ Provera 104 is given under the skin about every 12 to 14 weeks. A healthcare professional gives the subcutaneous shot. Follow your prescriber’s schedule.

What side effects should I expect?

▾
Changes in your bleeding pattern are the most common, and periods often stop over time. Headache, weight gain, injection site reactions and mood changes can also occur. Call your doctor for signs of a blood clot, liver problems, vision changes, severe belly pain or worsening depression.

Does the shot affect my bones?

▾
Yes, it can lower bone mineral density, and the loss may not fully come back after stopping. That is why it is not recommended for more than 2 years unless other options are inadequate. Tell me if you smoke, drink heavily or take steroids or seizure medicines, since they add to the bone risk.

Can other medicines affect how well it works?

▾
Yes. Medicines and herbs like St. John’s wort, rifampin, carbamazepine, phenytoin and topiramate can lower the effectiveness of hormonal birth control, so you may need a back-up method. Always tell me about everything else you take.

Will I be able to get pregnant after stopping?

▾
Fertility can take a while to return after the injections. In one study, about 68% of women who tried to conceive did so within 12 months of the last shot, and 93% within 18 months. The shot also does not protect against HIV or other sexually transmitted diseases.

Is Medroxyprogesterone available over the counter?

▾
No. Medroxyprogesterone is a prescription medicine: every Medroxyprogesterone product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Medroxyprogesterone first available?

▾
The earliest FDA record we hold for Medroxyprogesterone is from 1959: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Medroxyprogesterone was first used.

Who makes Medroxyprogesterone?

▾
23 companies currently list Medroxyprogesterone products in the FDA's NDC Directory, including Pharmacia & Upjohn Company LLC, A-S Medication Solutions, Bryant Ranch Prepack. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Medroxyprogesterone on HelloPharmacist

📊Medroxyprogesterone supplement interactions139 checked — ranked by severity 🌿Drug & Supplement CheckerMedroxyprogesterone vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Medroxyprogesterone NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Medroxyprogesterone Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Medroxyprogesterone forms and strengths (how it comes)

Medroxyprogesterone is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Provera
How this form is used
What it may be used for
  • Provera tablets treat secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance when no organic cause such as fibroids or uterine cancer is present.
  • Provera tablets help prevent endometrial hyperplasia in postmenopausal women with a uterus who take daily oral conjugated estrogens.
Important instructions
  • Provera tablets are taken by mouth once daily for a set number of days, depending on the condition.
  • Provera tablets for secondary amenorrhea may be started at any time.
  • Provera tablets for abnormal uterine bleeding are started on a set day of the menstrual cycle.
Available strengths 3 strengths
2.5 mg 5 mg 10 mg
72 FDA-listed product records ⓘ

Injection

Into a muscle · Under the skin
Brands Depo-Provera Depo-SubQ Provera
How this form is used
What it may be used for
  • Depo-Provera CI is used to prevent pregnancy in females of reproductive potential.
  • Depo-SubQ Provera 104 is used to prevent pregnancy and manage endometriosis-associated pain in females of reproductive age.
  • Medroxyprogesterone acetate injectable suspension is used to prevent pregnancy in females of reproductive potential.
Important instructions
  • Depo-Provera CI is given by deep intramuscular injection into the buttock or upper arm about every 3 months (13 weeks).
  • Depo-SubQ Provera 104 is given only by a healthcare professional, under the skin of the thigh or abdomen, about every 12 to 14 weeks.
  • Depo-Provera CI is not recommended for more than 2 years unless other birth control options are considered inadequate.
  • Depo-SubQ Provera 104 is not recommended for more than 2 years unless other options are considered inadequate.
Available strengths 2 strengths
104 mg/0.65 mL 150 mg/mL
47 FDA-listed product records ⓘ

Medroxyprogesterone on the U.S. market: products, makers and brands

How Medroxyprogesterone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

23 companies list 48 Medroxyprogesterone product records with the FDA, mostly as tablet, injection; the earliest marketing or approval year on record is 1959. Brand names on the directory include Provera, Amen, Curretab and 4 more; the rest are generics.

2
Dose forms ⓘ
23
Labelers (makers, repackagers, distributors)
6
Brand names
48
FDA-listed product records ⓘ
1959
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (15) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Pharmacia & Upjohn Company LLC13%
A-S Medication Solutions10%
Bryant Ranch Prepack8%
Mylan Pharmaceuticals Inc.6%
Remedyrepack Inc.6%
Teva Pharmaceuticals USA, Inc.6%
Other makers50%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Medroxyprogesterone is used (Medicaid data)

A general measure of how commonly Medroxyprogesterone is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Medroxyprogesterone is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

1,134,727
Medicaid prescriptions filled (Q1–Q4 2025)
$37.4M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Medroxyprogesterone prescribed? Of the 1,601 medications we measure, Medroxyprogesterone ranks #153 by Medicaid prescriptions — more than 90% of them.

Where Medroxyprogesterone ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #153 of 1,601
#148 Celecoxib 1,204,360 Rx #149 Ofloxacin 1,194,981 Rx #150 Nicotine Transdermal P... 1,178,062 Rx #151 Hydrochlorothiazide /... 1,175,772 Rx #152 Senna 1,155,349 Rx #153 Medroxyprogesterone 1,134,727 Rx #154 Azelastine Nasal Spray 1,133,133 Rx #155 Paroxetine 1,132,136 Rx #156 Promethazine 1,115,560 Rx #157 Norethindrone 1,115,474 Rx #158 Epinephrine 1,108,898 Rx

Utilization by Medroxyprogesterone product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 1 mL / 150 mg/mL injection is the most-dispensed Medroxyprogesterone product — about 37% of these Medicaid prescriptions.

1 ML medroxyprogesterone acetate 150 MG/ML Injection Most dispensed

415,797 Medicaid prescriptions (Q1–Q4 2025) 37% of Medroxyprogesterone prescriptions shown $16.7M gross reimbursement (before rebates) ≈ $40 per prescription (gross)

Summed across the 21 of 37 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1000126

1 ML medroxyprogesterone acetate 150 MG/ML Prefilled Syringe

364,514 Medicaid prescriptions (Q1–Q4 2025) 32% of Medroxyprogesterone prescriptions shown $16.5M gross reimbursement (before rebates) ≈ $45 per prescription (gross)

Summed across the 6 of 12 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1000153

medroxyprogesterone acetate 10 MG Oral Tablet

276,083 Medicaid prescriptions (Q1–Q4 2025) 24% of Medroxyprogesterone prescriptions shown $2.9M gross reimbursement (before rebates) ≈ $10 per prescription (gross)

Summed across the 5 of 49 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1000114

medroxyprogesterone acetate 5 MG Oral Tablet

38,626 Medicaid prescriptions (Q1–Q4 2025) 3% of Medroxyprogesterone prescriptions shown $432,797 gross reimbursement (before rebates) ≈ $11 per prescription (gross)

Summed across the 3 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1000141

medroxyprogesterone acetate 2.5 MG Oral Tablet

30,232 Medicaid prescriptions (Q1–Q4 2025) 3% of Medroxyprogesterone prescriptions shown $353,474 gross reimbursement (before rebates) ≈ $12 per prescription (gross)

Summed across the 3 of 22 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1000135

0.65 ML medroxyprogesterone acetate 160 MG/ML Prefilled Syringe

9,475 Medicaid prescriptions (Q1–Q4 2025) <1% of Medroxyprogesterone prescriptions shown $494,663 gross reimbursement (before rebates) ≈ $52 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1000156

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Medroxyprogesterone, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 39 of 134 listed Medroxyprogesterone NDCs with Medicaid activity.

Compare Medroxyprogesterone products

A representative set of FDA-listed product records for Medroxyprogesterone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 48 of 48 products — FDA National Drug Code Directory. See every product, package size and price: browse all 48 Medroxyprogesterone NDCs →

Medroxyprogesterone recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 2 Medroxyprogesterone recalls since July 2021. One of them is still ongoing and is listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class II Dec 18, 2024 · Eugia US LLC
CGMP Deviations
  • medroxyPROGESTERone Acetate Injectable Suspension, USP, 150mg per mL, Rx only, 1 mL Single-Dose Vial, Mfd in India for: Eugia US LLC, NJ 08520 NDC 55150-329-01 Shipper label: medroxyPROGESTERone Acet… Lots: Lot No.: 1MP24069, Exp.: 08/2026 FDA record D-0185-2025 →
Class II May 6, 2022 · Terminated · SUN PHARMACEUTICAL INDUSTRIES INC
Lack of assurance of sterility
  • medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Prefilled Syringe, 150 mg/mL, Rx only, Manufactured by Sun Pharmaceutical Industries Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, I… Lots: Lot #: HAC1951A, Exp 06/2023 FDA record D-1145-2022 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Medroxyprogesterone RxCUI 6691 4 dose forms · 13 strengths
  1. Dose form (SCDF) Injectable Suspension RxCUI 378653 In current FDA listings
    Clinical drug / strength (SCD) acetate 160 MG/ML RxCUI 1000374 acetate 200 MG/ML RxCUI 1000378
  3. Dose form (SCDF) Oral Tablet RxCUI 372739 In current FDA listings
    Clinical drug / strength (SCD) acetate 10 MG RxCUI 1000114 acetate 100 MG RxCUI 1000364 acetate 2.5 MG RxCUI 1000135 acetate 200 MG RxCUI 1000376 acetate 250 MG RxCUI 1000380 acetate 400 MG RxCUI 1000384 acetate 5 MG RxCUI 1000141 acetate 500 MG RxCUI 1000386

Look up RxCUI 6691 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Medroxyprogesterone costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Injection, Suspension · Intramuscular 150 mg/mL $50.99 per mL NDC details & price history
Injection, Suspension, Extended Release · Intramuscular 150 mg/mL $18.85–$22.85 per mL NDC details & price history
Injection, Suspension · Subcutaneous 104 mg/0.65 mL $77.43 per mL NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Medroxyprogesterone brand names

Medroxyprogesterone is sold under 7 brand names in the FDA directory — Provera, Amen, Curretab, Cycrin and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Provera Amen Curretab Cycrin Prodroxy Depo-Provera Depo-SubQ Provera

Who makes Medroxyprogesterone: manufacturers and labelers

23 companies list Medroxyprogesterone products with the FDA. By number of product records, the largest are Pharmacia & Upjohn Company LLC, A-S Medication Solutions, Bryant Ranch Prepack. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Pharmacia & Upjohn Company LLC 6 A-S Medication Solutions 5 Bryant Ranch Prepack 4 Mylan Pharmaceuticals Inc. 3 Remedyrepack Inc. 3 Teva Pharmaceuticals USA, Inc. 3 Amneal Pharmaceuticals LLC 2 Amphastar Pharmaceuticals, Inc. 2 Eugia US LLC 2 PD-Rx Pharmaceuticals, Inc. 2 Prasco Laboratories 2 Preferred Pharmaceuticals Inc. 2 Sun Pharmaceutical Industries, Inc. 2 American Health Packaging 1 Amneal Pharmaceuticals NY LLC 1 Coupler LLC 1 Hikma Pharmaceuticals USA Inc. 1 Mylan Institutional LLC 1 Northwind Health Company, LLC 1 NuCare Pharmaceuticals,Inc. 1 PharmPak, Inc. 1 Proficient Rx LP 1 Xiromed LLC 1

Medroxyprogesterone drug class (RxNorm)

Medroxyprogesterone belongs to the Progestin class.

Pharmacologic class Progestin
Drug family (ATC) Progestogens, Pregnen (4) derivatives, Progestogens

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Medroxyprogesterone page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Oct 9, 2022
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Medroxyprogesterone.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Medroxyprogesterone after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
24
Finished products in the current FDA directory
48
Companies listing them (makers, repackagers, distributors)
23
FDA labeler codes behind them ⓘ
24
Linked representative label ⓘ
PharmPak, Inc.
Linked label effective
Oct 9, 2022
Composite sections available
21
Linked SPL Set ID
1403a9a9-c04a-432f-8819-4850f779312e
Linked SPL Document ID
eaa58b56-e846-aab7-e053-2995a90a49c2
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. PharmPak, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →